Welcome to our dedicated page for Gelteq news (Ticker: GELS), a resource for investors and traders seeking the latest updates and insights on Gelteq stock.
Gelteq Limited (GELS) generates news across pharmaceuticals, nutraceuticals, medicinal cannabis and sports performance, reflecting its focus on gel-based oral delivery technologies. Company announcements highlight preclinical study results, commercial agreements and collaboration milestones that illustrate how its proprietary gel platform is being applied in multiple health-related markets.
Investors and observers following Gelteq’s news can expect updates on preclinical and clinical development, including bioavailability and pharmacokinetic data for gel-based formulations of antihistamines, medicinal cannabinoids and oil-soluble or poorly soluble drugs. These releases often compare Gelteq’s formulations to existing reference products and discuss implications for absorption, dosing and potential regulatory pathways.
Gelteq also issues news about commercial partnerships and distribution agreements. Recent announcements include a multi-year sales agreement with a healthcare and wellness distributor in China for a sugar-lowering nutritional gel, collaborations with nutraceutical partners launching products in the U.S., and sports performance partnerships with national flag football programs and professional leagues in Asia and Australia.
Additional news items cover strategic collaborations with academic and clinical institutions, such as product development agreements with Melbourne Health for HAMSB-based bowel polyp reduction products and preclinical research collaborations with university pharmaceutical science institutes. The company also communicates its participation in investor conferences and presentations outlining its growth strategy and market positioning.
This news feed allows readers to track Gelteq’s scientific progress, partnership activity and geographic expansion as it advances its gel-based oral delivery platform. For those monitoring the Drug Manufacturers – Specialty & Generic and healthcare technology space, Gelteq’s updates provide insight into how drug delivery innovations are being developed and commercialized.
Gelteq (NASDAQ: GELS) announces that its largest U.S. customer, Healthy Extracts, has increased its initial purchase order of collagen and Mynus sugar blocker gels by 50% due to high market demand. The production is underway with shipment expected in January 2025. This expansion follows Gelteq's strategic U.S. market entry, including the recent appointment of Adam Bendell as U.S. President. The partnership aims to provide improved delivery solutions for nutraceutical products, focusing on easier digestion and better absorption.
Gelteq (NASDAQ: GELS) announces the production of 400,000 units of its gel solution in November 2024. The production run includes nutraceutical products for sports, anti-aging, and weight loss, fulfilling orders for clients in the U.S. and Australia. Delivery is expected in January 2025, with sales extending to the UAE and Asia. The company states this production milestone follows their recent IPO and demonstrates their ability to execute large-scale sales while maintaining research and development activities. Gelteq also highlights their strengthened partnership with Monash Innovation Labs to ensure quality and scalability.
Gelteq (NASDAQ: GELS) has expanded its U.S. operations by appointing Adam Bendell as President of U.S. Operations. Bendell, who brings nearly a decade of experience in corporate strategy and retail operations, has previously worked with global brands including Deloitte Consulting, Calvin Klein, Tommy Hilfiger, and Cole Haan. The appointment aligns with Gelteq's growth strategy to scale operations in the U.S. market. The company specializes in developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, and pet care products.
Gelteq has successfully completed its initial public offering (IPO), raising US$5.2 million through the sale of 1,300,000 ordinary shares at US$4.00 per share. The company's shares began trading on the Nasdaq Global Market under the symbol GELS on October 29, 2024. The Benchmark Company acted as lead managing underwriter, with a 45-day option to purchase up to 195,000 additional shares for over-allotments. Gelteq, a biotechnology company specializing in ingestible gel technology, plans to use the proceeds for manufacturing, marketing, and R&D activities.